Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and Absolute Bioavailability of Ritlecitinib (PF-06651600) in Healthy Males
NCT03929510Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ritlecitinib tosilate in alopecia areata (2 arms), sponsored by Pfizer. Primary endpoints: Cumulative recovery of radioactivity in urine at Day 24 and Cumulative recovery of radioactivity in feces at Day 24. Started Apr 2019; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT03929510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03929510.